Citations

Showing 10 of 108135 citations.

Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome
Tetzloff, Katerina A. , Botha, Hugo , Martin, Peter R. , Senjem, Matthew L. , Gunter, Jeffrey L. , Spychalla, Anthony J., Petersen, Ronald C. , Jack, Clifford R. , Lowe, Val J. , Josephs, Keith A. , Whitwell, Jennifer L. , Strand, Edythe A. , Jack, Clifford R , Senjem, Matthew L , Botha, Hugo , Duffy, Joseph R. , Clark, Heather M. , Utianski, Rene L. , Machulda, Mary M. , Schwarz, Christopher G. , Reid, Robert I. , Knopman, David S.

Mayo Clinic

Brain | May 17, 2019 | Volume: 142 | Issue: 8 | Pages: 2466-2482

10.1093/brain/awz157 | PMID 31199471 Get It

Abstract Agrammatic aphasia affects grammatical language production and can result from a neurodegenerative disease. Although it typically presents with concomitant apraxia of speech, this is not always the case. Little is known about the clinical course and imaging features of patients that present with agrammatism in the absence of apraxia of speech, which we will refer to as progressive agrammatic aphasia. We aimed to make a detailed description of the longitudinal clinical, linguistic, and neuroimaging features of a cohort of 11 patients with progressive agrammatic aphasia to provide a complete picture of this syndrome. All patients underwent detailed speech and language, neurological and neuropsychological assessments, 3 T structural and diffusion tensor imaging MRI, 18F-fluorodeoxyglucose and Pittsburgh compound B PET. The 11 patients were matched by age and gender to 22 patients who had mixed apraxia of speech and agrammatism. The progressive agrammatic aphasia patients performed abnormally on tests of language, general cognition, executive function, and functional ability at baseline and declined in these measures over time. Only two patients eventually developed apraxia of speech, while parkinsonism was absent-to-mild throughout all visits for all patients. When compared to the patients with mixed apraxia of speech and agrammatism, the patients with progressive agrammatic aphasia performed better on tests of motor speech and parkinsonism but more poorly, and declined faster over time, on tests of general aphasia severity, agrammatism, and naming. The patients with progressive agrammatic aphasia also showed different neuroimaging abnormalities, with greater atrophy, hypometabolism and white matter tract degeneration in the prefrontal and anterior temporal lobes compared to patients with mixed apraxia of speech and agrammatism. These differences were more pronounced as the disease progressed. These results demonstrate that progressive agrammatic aphasia has a different clinical disease course and different underlying neuroanatomical abnormalities than patients with the more common syndrome of mixed agrammatism and apraxia of speech. This supports the distinction of progressive agrammatic aphasia and has implications for the classification of patients with agrammatic aphasia.
Quality Improvement Goals for Acute Kidney Injury
Kashani, Kianoush , Rosner, Mitchell H. , Lewington, Andrew , O’Donoghue, Dónal , Wilson, F. Perry , Nadim, Mitra K. , Silver, Samuel A. , Zarbock, Alexander , Ostermann, Marlies , Mehta, Ravindra L. , Kane‐Gill, Sandra L. , Pickkers, Peter , Bihorac, Azra , Siew, Edward D. , Frazee, Erin N. , Macedo, Etienne , Kellum, John A. , Tolwani, Ashita , Ronco, Claudio , Juncos, Luis A. , Rewa, Oleksa , Bagshaw, Sean M. , Mottes, Theresa , Liu, Kathleen D. , Heung, Michael , Wu, Vin‐Cent , Rewa, Oleksa G. , Wilson, F Perry , Mehta, Ravindra L , Ding, Xiaoqiang , Frazee, Erin N , Macedo, Etienne , Ronco, Claudio , Wu, Vin-Cent , Kane-Gill, Sandra L , Kashani, Kianoush B , Kellum, John A , Silver, Samuel A , Haase, Michael , Palevsky, Paul M. , Koyner, Jay L. , Forni, Lui G. , Bihorac, Azra , Bagshaw, Sean M , Juncos, Luis A , Ostermann, Marlies , Rewa, Oleksa G , Siew, Edward D

Mayo Clinic

Clinical Journal of the American Society of Nephrology | May 17, 2019 | Volume: 14 | Issue: 6 | Pages: 941-953

10.2215/cjn.01250119 | PMID 31101671 Get It

AKI is a global concern with a high incidence among patients across acute care settings. AKI is associated with significant clinical consequences and increased health care costs. Preventive measures, as well as rapid identification of AKI, have been shown to improve outcomes in small studies. Providing high-quality care for patients with AKI or those at risk of AKI occurs across a continuum that starts at the community level and continues in the emergency department, hospital setting, and after discharge from inpatient care. Improving the quality of care provided to these patients, plausibly mitigating the cost of care and improving short- and long-term outcomes, are goals that have not been universally achieved. Therefore, understanding how the management of AKI may be amenable to quality improvement programs is needed. Recognizing this gap in knowledge, the 22nd Acute Disease Quality Initiative meeting was convened to discuss the evidence, provide recommendations, and highlight future directions for AKI-related quality measures and care processes. Using a modified Delphi process, an international group of experts including physicians, a nurse practitioner, and pharmacists provided a framework for current and future quality improvement projects in the area of AKI. Where possible, best practices in the prevention, identification, and care of the patient with AKI were identified and highlighted. This article provides a summary of the key messages and recommendations of the group, with an aim to equip and encourage health care providers to establish quality care delivery for patients with AKI and to measure key quality indicators.
Establishing a Mutually Respectful Environment in the Workplace: A Toolbox for Performance Excellence
Duma, Narjust , Maingi, Shail , Tap, William D. , Weekes, Colin D. , Thomas, Charles R. Jr.

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 17, 2019 | Volume: No volume available | Issue: 39 | Pages: e219-e226

10.1200/edbk_249529 | PMID 31099664 Get It

Most health care professionals spend a substantial amount of their time at the workplace. Our interactions with team members can define our daily experiences, impact our work performance, and influence our overall job satisfaction. Over the last years, how we interact with colleagues and patients has changed with the introduction of social media, a tenser political climate, and an evolving health care system. In oncology, a team can be composed of medical students, clinicians, and support and administrative staff within a heavy emotional environment where some of our patients are facing the risk of early mortality and most are dealing with the unmeasurable burden of cancer. Many of these factors can increase the risk for professionalism lapses. We discuss common challenges faced in the practice of cancer care, including the generational gap between medical trainees and senior members, gender disparities, and microaggressions. Microaggressions represent verbal, behavioral, and environmental indignities that communicate hostile, derogatory, and negative slights that insult a target person or group. Microaggressions should not be accepted as the norm in the workplace. It is essential to recognize these negative behaviors and manage them effectively to reduce or even prevent the long-term toxicities that these behaviors can bring to the workplace environment. Ultimately, we must acknowledge that these issues exist and remember that education and collaboration are the pillars of an inclusive workplace. We owe such efforts to our patients who deserve good care, to our partners in the care of patients so that they feel supported and included, and to ourselves.
The Future of Wearable Technologies and Remote Monitoring in Health Care
Thompson, Carrie A. , Peterson, Susan K. , Beg, Muhammad Shaalan , Thompson, Carrie, Liao, Yue , Mandrola, John M

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 17, 2019 | Volume: No volume available | Issue: 39 | Pages: 115-121

10.1200/edbk_238919 | PMID 31099626 Get It

Mobile technology has become a ubiquitous part of everyday life and is changing the way we offer clinical care and perform clinical research. We have unprecedented access to data for one’s self-care as well as for sharing with health care providers. Meeting the challenge posed by the influx of wearable device data requires a multidisciplinary team of researchers, clinicians, software developers, information technologists, and statisticians. Although the possibility of what can be achieved with the ever-evolving wearable technologies seems to be unlimited, regulatory agencies have provided a framework to establish standards for clinical applications, which will also affect research applications. Clinical programs and electronic medical records vendors should prepare to establish a framework to implement these technologies into clinicians’ workflow and to allow feedback to measure the impact on clinical outcome. In this article, we discuss how a new brand of multidisciplinary care is evolving around mobile health devices and present a vision of up-and-coming technology in this space.
Many Shades of Disparities in Myeloma Care
Ganguly, Siddhartha , Mailankody, Sham , Ailawadhi, Sikander

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 17, 2019 | Volume: No volume available | Issue: 39 | Pages: 519-529

10.1200/edbk_238551 | PMID 31099639 Get It

Treatment of multiple myeloma (MM) has notably evolved with improved patient outcomes over the past few years. Several new drugs have become available, and large national and international clinical trials have set the stage for evidence-based medicine guidelines for the treatment of patients with MM. Although patient outcomes have undoubtedly improved, data increasingly show that several disparities exist at varying levels of health care and that these disparities make the care of patients heterogenous and potentially result in inferior outcomes. These disparities have been described with regard to patient age, race/ethnicity, rural-urban residence, socioeconomic status, and insurance type, among other factors. Looking at the global picture of MM care, there is substantial variation among different countries, primarily depending on the disparate availability of anti-MM drugs and access to quality health care across the world, limiting the delivery of innovative therapeutic approaches at the individual patient level. The causes of these national and international disparities could be multifactorial, intricate, and difficult to isolate. Yet the ongoing research in this field is encouraging, and there seems to be growing momentum to understand such disparities and their causes. It is hoped that this research will lead to solutions that can be implemented in the near future. This review focuses on certain aspects of disparities in MM care, highlighting disparities among different racial/ethnic subgroups, rural-urban differences in America, and global disparities at an international level.
Family-Based Next-Generation Sequencing Study Identifies an IL2RG Variant in an Infant with Primary Immunodeficiency
Bandari, Aravind K. , Bhat, Sunil, Archana, MV, Yadavalli, Sunita, Rajagopalan, Pavithra, Madugundu, Anil K. , Madkaikar, Manisha , Reddy, Kavita S., Pandey, Akhilesh , Pandey, Akhilesh , Pandey, Akhilesh , Patel, Krishna , Reddy, Kavita, Muthusamy, Babylakshmi

Mayo Clinic

OMICS: A Journal of Integrative Biology | May 17, 2019 | Volume: 23 | Issue: 5 | Pages: 285-290

10.1089/omi.2018.0196 | PMID 31100039 Get It

Abstract Primary immunodeficiencies (PIDs) are a rare and heterogeneous group of inherited genetic disorders that are characterized by an absent or impaired immune system. In this report, we describe the use of next-generation sequencing to investigate a male infant with clinical and immunological manifestations suggestive of a PID. Whole-exome sequencing of the infant along with his parents revealed a novel nucleotide variant (cytosine to adenine substitution at nucleotide position 252) in the coding region of the interleukin 2 receptor subunit gamma ( IL2RG ) gene. The mother was found to be a carrier. These findings are consistent with a diagnosis of X-linked severe combined immunodeficiency and represent the first such reported mutation in an Indian family. This mutation leads to an asparagine to lysine substitution ( p.Asn84Lys ) located in the extracellular domain of IL2RG, which is predicted to be pathogenic. Our study demonstrates the power of next-generation sequencing in identifying potential causative mutations to enable accurate clinical diagnosis, prenatal screening, and carrier female detection in PID patients. We believe that this approach, which is not a current routine in clinical practice, will become a mainstream component of individualized medicine in the near future.
Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future
Yadav, Siddhartha , Couch, Fergus J.

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 17, 2019 | Volume: No volume available | Issue: 39 | Pages: 61-74

10.1200/edbk_238987 | PMID 31099663 Get It

The field of germline genetic testing for breast cancer (BC) risk has evolved substantially in the last decade. The introduction of multigene panel testing (MGPT) led to an urgent need to understand the cancer risk associated with several genes included in the panels. Although the research on understanding the cancer risk associated with mutations in several genes continues, there is also a need to understand the modifying effects of race and ethnicity, family history, and BC pathology on the prevalence of germline mutations and associated BC risk. Furthermore, polygenic risk scores (PRSs) to predict BC risk in patients with or without germline mutations in cancer-predisposition genes are now available for clinical use, although data on the clinical utility of PRSs are lacking. In patients with advanced BC associated with BRCA1/2 mutation, olaparib and talazoparib are now approved for treatment. In addition, molecular profiling studies are being used to clarify the BC tumor biology in mutation carriers to identify potential therapeutic options. In this article, we discuss these advances in the field of germline genetic testing and highlight current limitations and implications for clinical care.
Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?
Tom, Martin C. , Buckner, Jan C. , Dietrich, Jörg , Parsons, Michael , Yu, Jennifer S. , Parsons, Michael W , Cahill, Daniel P.

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 17, 2019 | Volume: No volume available | Issue: 39 | Pages: 133-145

10.1200/edbk_238353 | PMID 31099638 Get It

Following the identification of key molecular alterations that provided superior prognostication and led to the updated 2016 World Health Organization (WHO) Central Nervous System (CNS) Tumor Classification, the understanding of glioma behavior has rapidly evolved. Mutations in isocitrate dehydrogenase (IDH) 1 and 2 are present in the majority of adult grade 2 and 3 gliomas, and when used in conjunction with 1p/19q codeletion for classification, the prognostic distinction between grade 2 versus grade 3 is diminished. As such, the previously often used term of “low-grade glioma,” which referred to grade 2 gliomas, has now been replaced by the phrase “lower-grade glioma” to encompass both grade 2 and 3 tumors. Additional molecular characterization is ongoing to even further classify this heterogeneous group of tumors. With such a colossal shift in the understanding of lower-grade gliomas, management of disease is being redefined in the setting of emerging molecular-genetic biomarkers. In this article, we review recent progress and future directions regarding the surgical, radiotherapeutic, chemotherapeutic, and long-term management of adult lower-grade gliomas.
Expansion of the clinical spectrum associated with AARS2‐related disorders
Srivastava, Siddharth , Butala, Ankur , Mahida, Sonal , Richter, John E. , Mu, Weiyi , VanGerpen, Jay A., Middlebrooks, Erik H. , Zee, David S. , Naidu, SakkuBai, Richter, John, VanGerpen, Jay, Middlebrooks, Erik H , Poretti, Andrea , Vernon, Hilary J. , Atwal, Paldeep S , Naidu, Sakkubai

Mayo Clinic

American Journal of Medical Genetics Part A | May 17, 2019 | Volume: 179 | Issue: 8 | Pages: 1556-1564

10.1002/ajmg.a.61188 | PMID 31099476 Get It

AbstractBiallelic pathogenic variants in AARS2, a gene encoding the mitochondrial alanyl‐tRNA synthetase, result in a spectrum of findings ranging from infantile cardiomyopathy to adult‐onset progressive leukoencephalopathy. In this article, we present three unrelated individuals with novel compound heterozygous pathogenic AARS2 variants underlying diverse clinical presentations. Patient 1 is a 51‐year‐old man with adult‐onset progressive cognitive, psychiatric, and motor decline and leukodystrophy. Patient 2 is a 34‐year‐old man with childhood‐onset progressive tremor followed by the development of polyneuropathy, ataxia, and mild cognitive and psychiatric decline without leukodystrophy on imaging. Patient 3 is a 57‐year‐old woman with childhood‐onset tremor and nystagmus which preceded dystonia, chorea, ataxia, depression, and cognitive decline marked by cerebellar atrophy and white matter disease. These cases expand the clinical heterogeneity of AARS2‐related disorders, given that the first and third case represent some of the oldest known survivors of this disease, the second is adult‐onset AARS2‐related neurological decline without leukodystrophy, and the third is biallelic AARS2‐related disorder involving a partial gene deletion.